Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) last session’s volume of 0.49 million shares was higher than its average volume of 0.34 million shares. The stock, after opening at $1.66, hit $1.64 through the close by scoring -2.96%.Cyclacel Pharmaceuticals, Inc. (CYCC) Analyst Opinion
Cyclacel Pharmaceuticals, Inc. has a consensus outperform rating from 1 Wall Street analysts, and the number of shares currently sold short amount to at least 12.9% of shares outstanding. The stock sank -52.46% last month and is down -69 this year. Wall Street is only getting more bullish on the stock, with 1 of analysts who cover CYCC having a buy-equivalent rating. Analysts have placed a $7 price target on Cyclacel Pharmaceuticals, Inc., suggesting a 326.83% gain from recent close. It’s currently trading about -84.95% below its 52-week high.Cyclacel Pharmaceuticals, Inc. Earnings Surprise
Cyclacel Pharmaceuticals, Inc. (CYCC) revenue totaled $200000 down 0% from the previous quarter.Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Intraday View
This stock (CYCC) is ahead of its 52-week low with 5.13%. Its last month’s stock price volatility remained 7.11% which for the week stands at 7.67%. The share price has moved backward from its 20 days moving average, trading at a distance of -19.43% and stays -49.62% away from its 50 days moving average. Over the last five days, shares have faced 0% losses and now is down -61.95% since hitting its 200-day moving average of $4.25. Cyclacel Pharmaceuticals, Inc. (CYCC) has made its way to a 12-month decline of -65.76%.
Turning to MacroGenics, Inc. (NASDAQ:MGNX), its shares were trading at $15.83 a retreat of $-0.61, on the trading floor. The stock, after opening at $16.28, touched a high of $16.32 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.7. MacroGenics, Inc. has 5 buy ratings, 2 holds and 0 sells even after the stock tumbled -52.46% from its high of $33.3 to a $538.85 million market value through last close.MacroGenics, Inc. (MGNX) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 1.73 to 1.73 during a month. Analysts set a 12-month price target of $31 a share. The target implies a 95.83% spike from where the shares are currently trading. Also, the current price highlights a discount of 177.95% to analysts’ high consensus price target.MacroGenics, Inc. (NASDAQ:MGNX) Intraday Trading
The counter witnessed a trading volume of 0.28 million shares versus an average volume of 0.26 million shares during last trading session. Its last month’s stock price volatility remained 4.66% which for the week approaches 5.28%. The lowest price the stock reached in the last trading day was $15.63 and compares with the $14.36 52-week low. The stock recovered 10.24% since its low point and has performed -22.55% year-to-date.